Y-Intercept (HK)’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Y-Intercept (HK)’s Portfolio VYNT Stock Details VYNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,321	Closed	-$9.27K	–	1448
2022 Q3	$9.27K	Buy	+3,321	New	+$12.5K	﹤0.01%	922

Other funds holding VYNT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Y-Intercept (HK)'s VYNT Position: Q4 2022 in Review

Y-Intercept (HK) sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q4 2022, closing a stake of 3,321 shares — an estimated $9.27K sold.

Y-Intercept (HK) first reported a position in VYNT in Q3 2022 and held it in 1 quarter. The position peaked at $9.27K in Q3 2022. 17 funds tracked by Wall St. Rank hold VYNT as of Q4 2022.

Y-Intercept (HK) reported no remaining Vyant Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Y-Intercept (HK) sold 3,321 Vyant Bio, Inc. Common Stock shares in Q4 2022, an estimated $9.27K.
Y-Intercept (HK) first reported a position in Vyant Bio, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
Y-Intercept (HK)'s Vyant Bio, Inc. Common Stock position peaked at $9.27K in Q3 2022.
17 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q4 2022.

Based on Y-Intercept (HK)'s 13F filing for Q4 2022, filed 14 Feb 2023.